Home › Enanta Pharmaceuticals Announces CHMP Positive Opinion For AbbVie's VIEKIRAX + EXVIERA Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis
 

Keywords :   


Enanta Pharmaceuticals Announces CHMP Positive Opinion For AbbVie's VIEKIRAX + EXVIERA Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis

2016-03-02 03:39:36| drugdiscoveryonline Home Page

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced recently that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for the use of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) without ribavirin (RBV) in chronic hepatitis C virus (HCV) infected genotype 1b (GT1b) patients with compensated cirrhosis (Child-PughA)

Tags: with positive opinion treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.05Melting Massage Bar Patented by Johnson & Johnson
03.05How the computer games industry is embracing AI
03.05Apple sees biggest fall in sales for a year
02.05Turkey halts trade with Israel over Gaza 'tragedy'
02.05Loop Industries and Ester Ltd. Announce Joint Venture
02.05The Oldham Group names Hunter Collins account manager
02.05NCBAs Sigrid Johannes promoted to Senior Director of Government Affairs
02.05University helps neighboring ranchers oust redcedars
More »